New drugs for hypertension: what do they offer?
| Autor: | Yoel Vivas, Alan H. Gradman |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Endothelin A Receptor Antagonists
Pyridines Adrenergic beta-Antagonists Blood Pressure Pharmacology Nebivolol chemistry.chemical_compound Fumarates Renin Internal Medicine Medicine Humans Benzopyrans Antihypertensive Agents Phenylpropionates business.industry Endothelin receptor antagonist Dihydropyridine Drugs Investigational Aliskiren Calcium Channel Blockers Amides Pyrimidines Treatment Outcome chemistry Ethanolamines Hypertension Darusentan Endothelin receptor business Clevidipine medicine.drug |
| Zdroj: | Current hypertension reports. 8(5) |
| ISSN: | 1522-6417 |
| Popis: | A new drug might make a positive contribution to existing therapies for hypertension by: 1) reducing blood pressure (BP) via a novel pharmacologic mechanism; 2) possessing pharmacologic or pharmacokinetic properties that make it superior to other members of its class; or 3) facilitating BP control in refractory patients. In this paper, we review four experimental agents that promise to advance therapeutics by one of these mechanisms. Aliskiren is the first in a new class of potent, orally effective renin inhibitors. Aliskiren produces dose-dependent BP reduction with few side effects and constitutes a novel pharmacologic approach to renin-angiotensin-aldosterone inhibition. Nebivolol is a third-generation, cardioselective beta-blocker that produces vasodilation and improves endothelial function via the l-arginine/nitric oxide pathway. Clevidipine is an ultra-short-acting, vascular-selective, dihydropyridine calcium antagonist that is being developed for intravenous use in acute hospitalized patients. Darusentan is an endothelin(A) selective endothelin receptor antagonist that is effective in achieving BP control in a significant percentage of patients who remain uncontrolled despite treatment with three or more antihypertensive drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink